ArticleNPJ Parkinson's disease2026
An eight-year follow-up of the CMSAR: assessing how the new MDS criteria and biomarkers impact diagnostic accuracy.
Article in NPJ Parkinson's disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple system atrophy (MSA) is a rare, progressive neurodegenerative disorder with high mortality and diagnostic uncertainty. We re-evaluated 80 cases from the Catalan MSA Registry (CMSAR), applying the 2022 MDS diagnostic criteria and cerebrospinal fluid biomarkers, including α-synuclein seeding assays (asyn-SAA) and neurofilament light chain (NfL). Clinical and biomarker reassessment was performed in 2022-2023. At re-evaluation, 20 patients were alive; 14 were reclassified as non-MSA and three as unclassifiable. MSA cases had shorter survival (8.8 vs 14.8 years, p = 0.001), and dysphagia predicted poorer outcomes. The 2022 criteria showed higher specificity (94% for clinically established, 71% for probable) than the 2008 criteria. NfL levels were significantly higher in MSA (p = 0.005) and predicted mortality. Asyn-SAA was negative in confirmed MSA cases and positive in three suspected Parkinson's disease cases. These findings support the added diagnostic value of integrating updated criteria and CSF biomarkers to improve MSA classification and long-term monitoring.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.